Sign In
Buy INBS
$2.44
-0.100 (-3.94%)
At Close: Jun 03, 2026
Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
08:30am, Tuesday, 02'nd Jun 2026
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
08:30am, Wednesday, 13'th May 2026
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, build
Comparing Establishment Labs (NASDAQ:ESTA) & Intelligent Bio Solutions (NASDAQ:INBS)
01:12am, Monday, 27'th Apr 2026
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Intelligent Bio Solutions (NASDAQ: INBS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast
Aeon Global Health (OTCMKTS:AGHC) vs. Intelligent Bio Solutions (NASDAQ:INBS) Head-To-Head Review
02:14am, Friday, 24'th Apr 2026
Aeon Global Health (OTCMKTS:AGHC - Get Free Report) and Intelligent Bio Solutions (NASDAQ: INBS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
09:15am, Monday, 20'th Apr 2026
Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes
INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission INBS implements enhanced security architecture to protect test int
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
08:30am, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing s
HealthEquity (NASDAQ:HQY) & Intelligent Bio Solutions (NASDAQ:INBS) Head to Head Comparison
01:46am, Monday, 02'nd Mar 2026
HealthEquity (NASDAQ: HQY - Get Free Report) and Intelligent Bio Solutions (NASDAQ: INBS - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two busines
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026
Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS's fingerprint drug testing t
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
08:30am, Thursday, 12'th Feb 2026
First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more tha
Short Interest in Intelligent Bio Solutions Inc. (NASDAQ:INBS) Increases By 187.3%
03:16am, Saturday, 31'st Jan 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 369
Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market Company anticipates full data analysis by the end of March 2026; data
